Mineralys Therapeutics Inc MLYS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-02-10 |
| Shares Out. | 88,120,000 |
| Website | mineralystx.com/ ↗ |
| Phone | 18883786240 |
| Employees | 76 |
| Net Income | -$39.3M |
| Free Cash Flow | -$136.4M |
| Total Assets | $652.9M |
| Total Liabilities | $14.7M |
| Equity | $638.1M |
About Mineralys Therapeutics Inc
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Mineralys Therapeutics Inc is a publicly traded company under the ticker symbol MLYS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
16 analysts (2026-07-01)